RegeneRx Biopharmaceuticals, Inc.
Industry
- Pharmaceuticals
- Biotechnology
- Large Molecule
- Medical Devices
- Biomaterials
Latest on RegeneRx Biopharmaceuticals, Inc.
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OliX, Hansoh Ink Licensing Pact To Deve
HanAll BioPharma Co. Ltd. and Daewoong Pharmaceutical Co. Ltd. have unveiled top-line results from the first US Phase III study for HL036, their investigational biologic for the treatment of dry ey
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in
ReGenTree LLC has announced mixed results from the second pivotal Phase III clinical trial (ARISE-2) in the US of RGN-259 for the treatment of dry eye. RGN-259’s global effects on dry eye syndrome a